Holen Sie sich die Stockscreener-App
57.00
0.41%
0.23
Handel nachbörslich:
57.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Another pharma giant eyes Houston for $1B plant with hundreds of jobs possible - KHOU
Bristol Myers Squibb eyes Houston for $1B pharmaceutical plant - The Business Journals
Bristol Myers Squibb partners with Hengrui Pharma to develop and test drugs early in China. - Pluang
Biopharma Collaboration: Bristol Myers Squibb Partners with Heng - GuruFocus
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape - Oncodaily
Rx Rundown: Bristol Myers Squibb, Isomorphic Labs, Partner Therapeutics and more - Medical Marketing and Media
AustralianSuper Pty Ltd Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Strategic Advisers Fidelity Alternatives Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Sivia Capital Partners, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Benzinga
Tempus AI Stock (TEM) Opinions on Bristol Myers Squibb Partnership Expansion - Quiver Quantitative
Bristol-Myers Squibb Company stock (US0897961004): Dividend paid May 1 - AD HOC NEWS
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience - The Joplin Globe
AI aims to reshape Bristol Myers’ cancer and Alzheimer’s drug trials - Stock Titan
Bristol-Myers Squibb stock (US1101221083): China deal worth up to $15.2B - AD HOC NEWS
Bristol Myers Squibb Company $BMY Shares Sold by Bank Julius Baer & Co. Ltd Zurich - MarketBeat
MCDONALD PARTNERS LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration - Genetic Engineering and Biotechnology News
Bristol-Myers Shuts Down Lawsuit Over Celgene Investor Rights - Bloomberg Law News
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Cortisone Shots Market 2026 | Merck & Co, Pfizer, Bristol-Myers Squibb, Novartis, Pharmascience etc. - openPR.com
Bristol-Myers Squibb stock (US0897961004): $15.2B Hengrui Pharma drug partnership - AD HOC NEWS
Bernstein reiterates Bristol-Myers Squibb stock rating on China deal By Investing.com - Investing.com India
BMY Partners with Hengrui for $15.2 Billion Early-Stage Drug Dev - GuruFocus
Bernstein reiterates Bristol-Myers Squibb stock rating on China deal - Investing.com
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Jiangsu Hengrui Pharmaceutical Signs $15.2 Billion Drug Deal With Bristol Myers Squibb Ahead of Trump’s China Visit - Daily Pioneer
M Stanley: HENGRUI PHARMA (01276.HK) Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company (BMY.US) to Accelerate Globalization - AASTOCKS.com
Bristol Myers Squibb and Hengrui Pharma sign major licencing deal - FinanceAsia
NJ Court Not Sure Bristol-Myers Investor Pled Negligence - Law360
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology - BioPharma APAC
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up - WSJ
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal - BioWorld News
BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology
Bristol Myers Squibb (BMY) Valuation Check After Recent Share Weakness And Mixed 2024 Earnings - simplywall.st
Bristol Myers Squibb inks $15.2B drug deal with Hengrui - NJBIZ
Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B - MedCity News
Bristol-Myers Squibb stock (US1101221083): Stock dips despite strong Q1 2026 earnings - AD HOC NEWS
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal By Investing.com - Investing.com Nigeria
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal - Investing.com UK
BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potentially $15.2 Billion - BioPharm International
Hengrui Pharma strikes $15.2 billion asset deal with BMS - The Pharma Letter
Hengrui Pharma and Bristol Myers Squibb Enter Strategic Collaboration to Advance Innovative Medicines - marketscreener.com
China's Hengrui, Bristol Myers Squibb sign collaboration, licensing deals - Reuters
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion - BioPharma Dive
BMS-Hengrui Pact Highlights China’s Rising Role in Drug Development - PharmTech.com
Hengrui Pharma and Bristol Myers Squibb to advance innovative medicines across oncology, hematology, immunology - BioSpectrum Asia
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal - BioSpace
China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS - Yicai Global
BMS, Hengrui strike $15.2B multi-asset pact - FirstWord Pharma
Hengrui & BMS Seal $15.2B Deal: China-US Pharma - Rediff MoneyWiz
Bristol Myers Squibb Expands Pipeline With Hengrui Multi Billion Drug Alliance - Yahoo Finance
Hengrui's Deal With Bristol Myers Squibb Should Ease Concerns Over Dealmaking Slowdown -- Market Talk - Moomoo
Bristol Myers Squibb Strikes $15.2 Billion Drug Development Deal With Hengrui Pharma - Benzinga
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B - Endpoints News
Hengrui, BMS Strike Huge $15.2bn Alliance For Bundle Of Preclinical Assets - Citeline News & Insights
Hengrui Pharma's Stock Jumps on Massive $1B Collaboration with Bristol-Myers - StockInvest.us
Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui - Bloomberg.com
Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up - marketscreener.com
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):